Glycemic Response to Oral Nutrition Supplements

N/ACompletedNCT02612675

Société des Produits Nestlé (SPN)13 enrolled

Overview

This will be a randomized, cross-over study of two oral nutrition supplements in individuals with Type 2 Diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

SINGLE

Enrollment

Conditions

Diabetes

Interventions

ONSOTHER

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 20-75 yrs * Type 2 diabetes controlled with diet or diet and oral agent, with the exception of sulfonylureas such as glimepiride (Amaryl), glipizide (Glucotrol/Glucotrol XL) and glyburide (DiaBeta, Micronase, Glynase Prestabs); meglitinides such as reaglinide (Prandin) and nateglinide (Starlix); and alpha-glucosidase inhibitors such as acarbose (Precose) and miglitol (Glyset) * Hemoglobin A1C less than 9.0% * Fasting blood glucose less than 180 mg Exclusion Criteria: * Allergy to milk protein or any other component of the formula

Locations (1)

Diabetes & Glandular Disease Clinic, PA

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Area under the blood glucose curve (AUC 0-240)

Time frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.